Factors that influence the measurement of prostate cancer DNA ploidy and proliferation in paraffin embedded tissue evaluated by flow cytometry

Modern Pathology

Volumn 14, Issue 9, 2001, Pages 906-912

  So, Mathew J ^a   Cheville, John C ^b   Katzmann, Jerry A ^b   Riehle, Darren L ^b   Lohse, Christine M ^b   Pankratz, V Shane ^b   Sebo, Thomas J ^b  

^a SWARTHMORE COLLEGE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Carcinoma; DNA ploidy; Flow cytometry; High grade prostatic intraepithelial neoplasia; Needle track; Prostate; Prostatectomy; Tumor volume

Indexed keywords

DNA; EOSIN; FORMALDEHYDE; HEMATOXYLIN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBEDDING; EPITHELIUM CELL; FIBROHISTIOCYTOMA; FLOW CYTOMETRY; HISTOGRAM; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; STROMA CELL;

ADULT; AGED; CELL DIVISION; DNA, NEOPLASM; FLOW CYTOMETRY; G2 PHASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLOIDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; S PHASE;

EID: 0034827803     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880410     Document Type: Article

References (40)

1. Stage D1 prostatic adenocarcinoma: Significance of nuclear DNA ploidy patterns studied by flow cytometry
2. Prognostic significance of DNA ploidy in carcinoma of prostate
3. Stage C prostatic adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis
4. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis
5. Prognostic importance of nuclear DNA content measured by flow cytometry for patients with adenocarcinoma of the prostate
6. Flow cytometry as a predictive modality in prostate cancer
7. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: Influence on prognosis
8. S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1
9. Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate
10. Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer
11. Analysis of prostate cancer by flow cytometry and correlation with Gleason scores
12. Flow-cytometric analysis of deoxyribonucleic acid content in advanced ovarian carcinoma: Its importance in long-term survival
13. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer
14. Prognostic indicators in prostatic cancer
15. The TNM system of 1992
16. Diagnostic and prognostic markers for human prostate cancer
17. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation
18. Histopathology of localized prostate cancer. Consensus conference on diagnosis and prognostic parameters in localized prostate cancer
19. Progression and survival in prostatic adenocarcinoma: A comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy
20. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA less than 10 ng/ml treated with conformal external beam radiation therapy
21. Combining volume-weighted mean nuclear volume with Gleason score and clinical stage to predict more reliably disease outcome of patients with prostate cancer
22. Stage B prostate cancer. Correlation of DNA ploidy analysis with histological and clinical parameters
23. Should Gleason score 7 prostate cancer be considered a unique grade category?
24. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
25. Prognostic significance of tumor grade and stage in the patient with carcinoma of the prostate
26. Proliferative index determination in prostatic carcinoma tissue: Is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?
27. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer
28. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer
29. The role of nuclear DNA ploidy in the prognosis and management of patients with prostate cancer
30. DNA ploidy measurements in prostate cancer: Differences between image analysis and flow cytometry and clinical implications
31. Comparison between image and flow cytometry. A priori factors that influence technique
32. Prognostic value of deoxyribonucleic acid content in prostate cancer: A review of current results
33. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
34. National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening
35. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
36. Digital image analysis
37. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma
38. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate
39. p27(Kip1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis
40. Biological determinants of cancer progression in men with prostate cancer